Results show the bispecific antibody is effective in an earlier line of treatment. The phase 3 STARGLO study, which is evaluating glofitamab plus chemotherapy in patients with relapsed or refractory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback